DFTX MEXC RealStocks
Own real DFTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 07:55:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Definium Therapeutics, Inc. (DFTX) operates in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector and is listed on NASDAQ. The stock is currently priced at $32.09, with a market capitalization of $4.52B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.62 to $49.70. This page covers its latest market performance, valuation, price trends and company information.
$4.52B | |
$32.70 | |
$33.35 | |
$31.45 | |
$33.00 | |
664.80K | |
1.97M | |
-- | |
$49.70 | |
$14.62 | |
-- | |
-- |
Definium Therapeutics, Inc. (DFTX) last closed at $32.09 as of 2026-11-14 00:56:00, down 2.76% ($0.91) from the previous close of $33.00.
During the latest regular trading session, DFTX traded between $31.45 and $33.35, with a volume of 664.80K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Definium Therapeutics, Inc. (DFTX) moved from $30.36 to $32.09, representing a gain of 5.70% ($1.73).
The stock traded between $30.17 and $35.97 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.33 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 49.8%
DFTX is currently trading at $32.09, placing it 49.8% of the way from its 52-week low of $14.62 to its 52-week high of $49.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
| Industry | MEDICINAL CHEMICALS & BOTANICAL PRODUCTS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Definium Therapeutics, Inc. (DFTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DFTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DFTX shares and USD.
DFTX Shares to USD
1.00 DFTX shares = 32.092 USD
Calculations are estimates based on the latest available price and are for reference only.